1. Use of a compound binding to the sigma receptor for the treatment or prevention of pain developing due to chemotherapy. ! 2. Use according to claim 1, wherein the compound binding to the sigma receptor is used to prevent the development of pain developing due to chemotherapy. ! 3. Use according to claim 1, wherein the compound binding to the sigma receptor is used for the treatment of pain developing due to chemotherapy. ! 4. Use according to claim 3, wherein the pain is neuropathic pain, allodynia or hyperalgesia. ! 5. Use according to claim 4, wherein the neuropathic pain is selected from peripheral neuropathic pain, allodynia kauzalgii, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. ! 6. Use according to claim 1, characterized in that the compound may be in neutral form, in the form of a base or an acid in the form of a salt, preferably a physiologically acceptable salt thereof, in the form of a solvate or a polymorph and / or in the form of its racemate, pure stereoisomers, in particular enantiomers or diastereomers, or in the form of mixtures of stereoisomers, in particular enantiomers or diastereomers, in any suitable mixing ratio. ! 7. Use according to claim 1, characterized in that said compound binding to the sigma receptor has a value IC50≤5000 nM, preferably in that said compound binding to the sigma receptor has a value IC50≤1000 nM, more preferably in that said compound binding to the sigma receptor has a value IC50≤500 nM, most preferably in that said compound binding to the sigma receptor has a value IC50≤250 nM.